



Diabetes Dashboard - Active Employees, Spouses, and Dependents

Prevalence & Total Cost

Diabetic Pats per 1000




Total Cost of Diabetes - Allowed Amount Med & Rx




Risk Score Trend & Comparison

DCG Risk Score




Impact of Diabetes within Population


% of Patients with Pre-Diabetes, T1DM & T2DM



Allow Amt PMPY Med & Rx




Impact of Diabetes to Patient Count & Cost




\*Norm is based on 4Q23 Semi-Annual MS Norms

Disease Stage - by Prevalence



Disease Stage - by Total Cost



Disease Stage - Department/Group


Diabetes Episodes by Disease Stage by Department/Group			
Top 5 Departments/Groups by Total Episodes	Stage 1	Stage 2	Stage 3
Health & Social Services	48%	48%	4%
University of Delaware Actives	59%	39%	2%
Christina School District	53%	43%	4%
Correction	52%	45%	3%
Red Clay School District	49%	47%	4%

Top 5 departments/groups are chosen based on total number of episodes

HEDIS Quality Indicators and Compliance

HEDIS Quality Measures - Endocrine	FY 23	FY 24	YoY Change	2022 MS	Diff from
				Norm	Norm
HEDIS BPD Diabetes Blood Pressure Control	2%	4%	2%	9%	5%
HEDIS EED Diabetes Eye Exam	53%	54%	1%	31%	23%
HEDIS KED Kidney Health Evaluation for Pats w Diabetes	42%	41%	0%	37%	4%
HEDIS SPC Statin Therapy w ASCVD	81%	82%	1%	80%	1%
HEDIS SPD Statin Therapy w Diabetes	65%	64%	-1%	62%	3%
HEDIS SPD Statin Therapy w Diabetes Adherence	74%	74%	-1%	73%	0%
<b>Endocrine Total (excludes HbA1c Measures)</b>	<b>44%</b>	<b>44%</b>	<b>0%</b>		

Total Endocrine HEDIS Quality Measure





Only included locations with at least 30 members in the denominator

# Delaware GHIP Diabetes Dashboard, FY 24

## Diabetes Dashboard - Active Employees, Spouses, and Dependents

Utilization of Services					Utilization of Services Specific to Diabetes Care - Current Rolling Year												
	Diabetic Patients		Non-Diabetic Patients		Service Classification	Members with Diabetes						Members without Diabetes					
	Jul 2023 - Jun 2024	Trend	Jul 2023 - Jun 2024	Trend		Allowed Amount Med & Rx	% of Total Diabetes Spend	Patients Med or Rx	% of Total Diabetes Patients	Allow Amt Per Pat Med and Rx	OOP Per Pat Med & Rx	Allowed Amount Med & Rx	% of Total Spend	Patients Med or Rx	% of Total Patients	Allow Amt Per Pat Med and Rx	OOP Per Pat Med & Rx
Admits Per 1000 Acute	83.4	-9.1%	48.8	-5.8%													
Days LOS Admit Acute	6.5	21.7%	4.2	-10.4%	OP Prof & Svcs	\$80.5M	42%	9,464	100%	\$8,509	\$325	\$329.5M	50%	83,030	97%	\$3,969	\$193
Visits Per 1000 ER	406.5	-2.7%	248.9	-1.2%	Rx Non-Specialty	\$48.2M	25%	8,923	94%	\$5,399	\$374	\$63.4M	10%	67,659	79%	\$937	\$99
Visits Per 1000 Prev Adult	632.9	7.9%	543.3	4.5%	Inpatient	\$34.2M	18%	737	8%	\$46,455	\$34	\$125.0M	19%	4,299	5%	\$29,083	\$48
Visits Per Pat OP Prof	21.5	-0.2%	12.2	0.0%	Rx Specialty	\$15.9M	8%	635	7%	\$25,034	\$140	\$83.1M	13%	3,422	4%	\$24,297	\$184
Days Supply Per Pat Rx	1,329.6	-2.4%	417.9	1.9%	ER	\$11.3M	6%	2,011	21%	\$5,617	\$11	\$54.8M	8%	13,493	16%	\$4,061	\$14
					<b>Total</b>	<b>\$190.1M</b>	<b>100%</b>	<b>9,473</b>	<b>100%</b>	<b>\$20,071</b>	<b>\$692</b>	<b>\$655.9M</b>	<b>100%</b>	<b>85,211</b>	<b>100%</b>	<b>\$7,698</b>	<b>\$279</b>

Rx Spend and Utilization by Antidiabetic Class							Top 10 Drugs for Diabetes Patients - Current Rolling Year									
Therapeutic Class	Days Supply per Patient Rx			Net Pay PMPY Rx			Product Name	Therapeutic Class	Allowed Amount Rx	% of Total	Patients Rx	% of Patients	Days Supply per Patient	Allow Amt per Patient	OOP per Patient	
	Jul 2023 - Jun 2023	Jul 2023 - Jun 2024	% Diff	Jul 2023 - Jun 2023	Jul 2023 - Jun 2024	% Diff										
MEG, TZD and Misc	265	255	-4%	\$320	\$265	-17%	JARDIANCE	Antidiabetic Ag, SGLT Inhibitr	\$4,349,360	7%	952	11%	243	\$4,569	\$159	
SGLT	252	250	-1%	\$657	\$707	8%	TRULICITY	Antidiabetic Agents, Misc	\$3,774,231	6%	595	7%	196	\$6,343	\$169	
Sulfonylureas	257	256	0%	\$2	\$4	44%	OZEMPIC 1 MG DOSES	Antidiabetic Agents, Misc	\$3,493,153	5%	770	9%	140	\$4,537	\$129	
Insulins	310	287	-7%	\$785.94	\$491.71	-37%	OZEMPIC 0.25 MG OR 0.5 MG DOS	Antidiabetic Agents, Misc	\$3,219,802	5%	886	10%	122	\$3,634	\$121	
GLP-1 - Weight Loss	8	129	1518%	\$0.47	\$281.93	60143%	MOUNJARO	Antidiabetic Agents, Misc	\$3,081,695	5%	568	6%	150	\$5,426	\$159	
GLP-1 - Diabetes	217	227	5%	\$1,404.09	\$1,879.14	34%	OZEMPIC 2 MG DOSES	Antidiabetic Agents, Misc	\$2,194,067	3%	430	5%	156	\$5,102	\$136	
<b>Total</b>	<b>473</b>	<b>449</b>	<b>-5%</b>	<b>\$3,169</b>	<b>\$3,629</b>	<b>15%</b>	WEGOVY	Antidiabetic Agents, Misc	\$2,131,711	3%	353	4%	131	\$6,039	\$159	
							FARXIGA	Antidiabetic Ag, SGLT Inhibitr	\$2,119,984	3%	456	5%	254	\$4,649	\$169	
							RYBELSUS	Antidiabetic Agents, Misc	\$1,562,734	2%	255	3%	201	\$6,128	\$147	
							SKYRIZI	Immunosuppressants, NEC	\$1,339,242	2%	24	0%	215	\$55,802	\$0	
							<b>Top 10 Total</b>		<b>\$27,265,980</b>	<b>43%</b>	<b>5,289</b>	<b>59%</b>	<b>177</b>	<b>\$5,155</b>	<b>\$147</b>	
							<b>Total</b>		<b>\$64,067,841</b>	<b>100%</b>	<b>8,926</b>	<b>100%</b>	<b>1,330</b>	<b>\$7,178</b>	<b>\$384</b>	








Diabetes Dashboard - Active Employees, Spouses, and Dependents

Outcomes for Type 2 Diabetes (T2DM) Patients by GLP-1 Utilization and Year

	T2DM Patients With At Least One GLP-1 <sup>1</sup>				T2DM Patients With At Least 270 Days Supply of GLP-1s in Each Year <sup>2</sup>				Supply of Non-GLP-1s in Each Year <sup>3</sup>			
	Jun 2021 - May 2022	Jun 2022 - May 2023	Jun 2023 - May 2024	PRY to CRY Trend (% or pp)	Jun 2021 - May 2022	Jun 2022 - May 2023	Jun 2023 - May 2024	PRY to CRY Trend (% or pp)	Jun 2021 - May 2022	Jun 2022 - May 2023	Jun 2023 - May 2024	PRY to CRY Trend (% or pp)
Patients	1,147	1,581	2,096	32.6%	508	664	1,010	52.1%	1,430	1,508	1,699	12.7%
Medical Allowed Cost Per Patient - All Dx	\$13,686	\$13,838	\$13,170	-4.8%	\$12,215	\$13,479	\$11,111	-17.6%	\$18,736	\$16,078	\$17,077	6.2%
Rx Allowed Cost Per Patient - All Rx	\$13,439	\$13,401	\$14,066	5.0%	\$17,376	\$17,915	\$17,718	-1.1%	\$5,206	\$5,700	\$6,616	16.1%
Total Allowed Cost Per Patient - All Claims	\$27,078	\$27,196	\$27,216	0.1%	\$29,592	\$31,353	\$28,828	-8.1%	\$23,911	\$21,727	\$23,630	8.8%
Days Supply Per Patient - All Rx	2079	2018	1961	-2.8%	2,472	2,349	2,259	-3.9%	1,570	1,599	1,546	-3.3%
Days Supply Per Patient - Diabetes GLP-1 Rx	232	215	220	2.5%	339	326	301	-7.8%	---	---	---	---
Days Supply Per Patient - Diabetes Rx (Excludes GLP-1)	686	621	587	-5.5%	860	801	710	-11.4%	393	398	389	-2.0%
Percentage of Diabetes Patients With At Least One Flare-up	3.0%	3.3%	2.1%	-1.2%	2.6%	2.7%	1.5%	-1.1%	2.6%	2.5%	2.9%	0.4%
Diabetes Patients % Eye Exam (Medical Claims)	55.3%	62.5%	60.8%	-1.7%	58.2%	67.7%	63.9%	-3.8%	52.6%	58.6%	59.3%	0.8%

- Members who had at least one medical claim with a principal diagnosis of type 2 diabetes during a given time period, and who had at least one script for an antidiabetic GLP-1 medication during a given time period.
- Members who had at least one medical claim with a principal diagnosis of type 2 diabetes during each time period, and who had at least 270 days supply of an antidiabetic GLP-1 medication during each given time period.
- Members who had at least one medical claim with a principal diagnosis of type 2 diabetes during each time period, who had at least 270 days supply of a non-GLP-1 antidiabetic medication during each time period, but who have not had any antidiabetic GLP-1 scripts across the history of the database.



**Struggling** - Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple high-severity acute conditions and/or medium-severity chronic conditions.

**In-Crisis** - Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple severe acute and/or chronic conditions.